- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04393168
Proof-of-concept Study of LymphMonitor 1.0 to Assess the Lymphatic Vessel Function
Proof-of-concept Interventional Study to Evaluate the Feasibility of the New Method, LymphMonitor 1.0, to Assess Lymphatic Function, Consisting of Indocyanine Green-based Lymphatic Specific Tracer. and a Custom Fluorescence Measuring Investigational Device LymphMeter 1.0.
Lymphedema is the consequence of injured lymphatic system and is characterized by chronic, often disabling swelling of am affected body part, often arm or leg. In the western world secondary lymphedema arises most commonly after removal lymph nodes in an operation as a part of cancer treatment (for example from the armpits or the groin region), however it may also develop as a result of radiation, any other operation, infection or injury that destroys a part of lymphatic system. The disease often develops even years after the event. While there is no cure for lymphedema at present, early detection would ensure timely physiotherapy and application of compression garments that significantly slow down or stop the progression of the disease. However, presently used methods of that are used for diagnosis and evaluating the stage of the disease, are either invasive and expensive or inaccurate and can only be performed at specialized medical centres.
Therefore, we developed a simple, affordable and accurate technology, LymphMonitor 1.0 that can allow for testing how efficiently the lymphatic system is functioning. The test can be performed at the local medical centre or potentially even at home.
In this study, we investigate whether LymphMonitor 1.0 technology can distinguish between a healthy and a diseased lymphatic system (in lymphedema). This method may allow early diagnosis of lymphedema so that the development of the disease can be detected and prevented early enough. By participating in the study the lymphedema patients are making an important contribution to increasing the quality of life of lymphedema patients. In LymphMonitor 1.0 method method, a solution of a safe fluorescent dye, indocyanine green, is injected painlessly using tiny microneedles, MicronJet600TM, directly into the skin of the arm or leg. After injection, this dye is removed from the skin only through the lymphatic vessels. The intensity of the fluorescence signal corresponds to the amount of dye left in the skin. The decrease in the fluorescence signal after the injection is measured on the surface on the skin using a new device, LymphMeter 1.0. The faster the dye (and that fluorescence signal) disappears from the surface of the skin, the better the lymphatic system works. Therefore in the arm or leg affected by lymphedema the fluorescence signal will decrease much slower compared to the healthy one.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8091
- University Hostpial Zurich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- informed consent as documented by signature
- females and males 18 - 75 years old,
- established (stage 2 or higher) unilateral secondary arm or leg lymphedema resulting from lymphadectonomy, radiation or any other surgical treatment, infection or injury.
- good general health status.
Exclusion criteria:
- critical illness (active cancer, renal failure, hepatic dysfunction)
- active infection
- blood vascular malformations or diseases
- scleroderma
- primary lymphedema
- patients who underwent any surgical procedures for treatment of lymphedema (e.g. lymphovenous anastomosis, liposuction, lymph node transfer).
- contraindications to use ICG (VERDYE), i.e.
- patients with hypersensitivity to ICG or to sodium iodide
- patients with hypersensitivity to iodine,
- patients with hyper-thyroidism, patients with autonomic thyroid adenomas
- patients in which the injection of VERDYE was poorly tolerated in the past it must not be used again, since severe anaphylactic reactions might occur.
- hypersensitivity to albumin or its excipients
- women, who are pregnant (pregnancy test will be performed in case of women who did not undergo menopause),
- women who are breast feeding ,
- enrolment of the investigator, his/her family members, employees and other dependent persons,
- known or suspected non-compliance, drug or alcohol abuse,
- inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
- participation in another study with investigational drug within the 30 days preceding and during the present study,
- previous enrolment into the current study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with unilateral arm or leg lymphedema
|
The indocyanine green in 5% human albumin solution (tracer) (50 μL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections.
The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h.
In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour.
Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam.
The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs.
The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Areas under the normalized clearance curves (AUCs)
Time Frame: Fluorescence values measured immediately after injection and 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours after injection.
|
Areas under the normalized clearance curves (AUCs) in healthy and lymphedema limbs measured over 3 hours after injection.
To obtain the clearance curve, the fluorescence intensity values at the injection sites in healthy and lymphedema extremities at pre-determined timepoints
|
Fluorescence values measured immediately after injection and 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours after injection.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
other clearance parameters: clearance constant (k) and half-life of clearance (t1/2); (healthy versus diseased).
Time Frame: Fluorescence values measured immediately after injection and 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours after injection.
|
Fluorescence values measured immediately after injection and 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours after injection.
|
|
Correlation/no correlation of clearance parameters with the extent of the swelling (limb volume) in lymphedema patients.
Time Frame: 3 hours
|
3 hours
|
|
dimensions of the injected dye depot measured by FluoBeam
Time Frame: Dimensions will be measured immediately after injection and 1.5 hours and 3 hours after injection.
|
Images of the injection site over time will be recorded using Fluobeam at different and analysed.
|
Dimensions will be measured immediately after injection and 1.5 hours and 3 hours after injection.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety outcomes
Time Frame: 3 hours
|
Specific safety outcomes in this study will consist of any signs of potential allergic reactions and irritation of injection sites or any other intolerances
|
3 hours
|
Safety outcomes
Time Frame: Through the study completion, an average of 5 hours
|
Any adverse effects (AEs) and serious adverse effects (SAEs) (expected and unexpected will be recorded
|
Through the study completion, an average of 5 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nicole Lindenblatt, M.D, PhD, University Hostpial Zurich
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- POCLymphMonitor 1.0
- 2019-01823 (Registry Identifier: SNCTP clinical trials registry)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphedema
-
Lymphatica Medtech SATerminatedLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmSwitzerland
-
Tactile MedicalVanderbilt University Medical CenterRecruitingLymphedema | Lymphedema, Secondary | Lymphedema; Surgical | Lymphedema of Face | Lymphedema Due to RadiationUnited States
-
ThuasneUniversity Hospital, Tours; Delta ConsultantsCompletedLymphedema, Secondary | Lymphedema of Leg | Lymphedema Congenital | Lymphedema PrimaryFrance
-
Maastricht University Medical CenterRadboud University Medical Center; Erasmus Medical CenterRecruitingLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmNetherlands
-
Odense University HospitalDanish Cancer SocietyActive, not recruitingPathologic Processes | Neoplasms | Skin Diseases | Lymphatic Diseases | Postoperative Complications | Breast Cancer | Breast Diseases | Lymphedema | Breast Neoplasm | Surgery | Secondary Lymphedema | Breast Cancer Lymphedema | Lymphedema, Breast Cancer | Lymphedema of Upper Limb | Lymphedema Arm | Iatrogenic Lymphedema | A... and other conditionsDenmark
-
Swansea Bay University Health BoardSwansea University; Huntleigh Healthcare Ltd; Lymphoedema Wales Clinical NetworkCompleted
-
ResMedLymphatic Solutions, LLCCompletedLymphedema | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema PrimaryUnited States
-
University of OttawaMcGill University; Horizon Health Network; University of New Brunswick; New Brunswick...UnknownLymphedema of Upper Limb | Mastectomy Related Lymphedema | Lymphedema of Lower Extremity
-
Odense University HospitalZealand University Hospital; Vejle Hospital; Herlev and Gentofte HospitalRecruitingLymphedema | Breast Cancer Lymphedema | Lymphedema, Breast Cancer | Lymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema Arm | Lymphedema; SurgicalDenmark
-
University Hospital, MontpellierCompletedPrimary Lymphedema Secondary LymphedemaFrance
Clinical Trials on Lymphatic clearance measurement
-
Thomas MuellerUnknownKidney Neoplasms | Adult Polycystic Kidney Disease | Kidney DysfunctionSwitzerland
-
Central Hospital, Nancy, FranceRecruiting
-
University Hospital, GhentCompletedCritical Illness | Renal FunctionBelgium
-
Azienda Socio Sanitaria Territoriale della Valle...RecruitingCopd | Bronchiectasis AdultItaly
-
University Hospital, MontpellierCompletedChronic Kidney DiseasesFrance
-
Sultan Abdulhamid Han Training and Research Hospital...Istanbul Health Sciences UniversityCompletedVenous Insufficiency | Venous Leg Ulcer | Lymphatic DiseaseTurkey
-
University of FloridaNot yet recruiting
-
The Second Hospital of Hebei Medical UniversityUnknown
-
Dharmais National Cancer Center HospitalRecruitingBreast Cancer Related Lymphedema | Lymphedema ArmIndonesia
-
Moritz WagnerBezirkskrankenhaus St. Johann in TirolCompletedKnee Osteoarthritis | Rehabilitation | Total Knee Arthroplasty | Manual Lymphatic Drainage | MLDAustria